ClinicalTrials.Veeva

Menu

Application Value of Whole-procedure Optimization for Catheter Ablation of Atrial Fibrillation

Z

Zhengzhou University

Status

Enrolling

Conditions

Atrial Fibrillation

Treatments

Procedure: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
Procedure: Pulmonary vein isolation plus superior vena cava isolation

Study type

Observational

Funder types

Other

Identifiers

NCT06145906
HenanPPH Cardiology

Details and patient eligibility

About

The success rate of single-procedure atrial arrhythmia-free survival particularly ranged from 40% to 66% in persistent AF ablation. However, The surgical Cox maze III procedure has been established to be an effective curative strategy for AF with an AF-free survival rate of more than 95%. The main reason is the difficulty of creating continuous, transmural, and durable lesions by catheter ablation, especially when the procedure is performed on some complex anatomical structures in which epicardial muscular bundles may serve as components of the reentrant circuits.

The durability of the conduction block is a crucial factor for long-term effective AF ablation since previous studies reported that the reconnected Pulmonary veins contributed to the atrial tachycardia recurrence after persistent AF ablation. In addition, it is possible that the inadequate lesions accidentally produce new arrhythmogenic substrates. Therefore, new and better techniques are always chosen to minimize the reconnection of Pulmonary vein isolation (PVI) and additional ablation.

For paroxysmal AF, the ablation strategy of PVI plus superior vena cava isolation is chosen while PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus (CTI) for persistent AF. Any symptomatic or asymptomatic atrial arrhythmia lasting more than 30 seconds was regarded as an AF recurrence after a 3-month blanking period. The primary outcome was defined as 12-month atrial arrhythmia-free survival. The secondary outcomes include the block rate of PVI, superior vena cava isolation, and all linear ablations.

Enrollment

400 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Radiofrequency catheter ablation for the first time
  • AF rhythm recorded by ECG

Exclusion criteria

  • Thrombosis in left atrium
  • Left ventricular ejection fraction of < 35%
  • Abnormal thyroid function
  • Previous history of AF radiofrequency ablation and CABG
  • Left atrium diameter of > 65 mm or the volume of > 200 ml

Trial design

400 participants in 2 patient groups

Paroxysmal AF group
Description:
AF that terminates spontaneously or with intervention within 7 days of onset
Treatment:
Procedure: Pulmonary vein isolation plus superior vena cava isolation
Persistent AF group
Description:
AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion (drugs or electrical cardioversion) after ≥7 days
Treatment:
Procedure: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus

Trial contacts and locations

1

Loading...

Central trial contact

Yingjie Chu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems